Dose escalation results of a phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in patients (Pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML).

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Erba, HP; Becker, PS; Shami, PJ; Grunwald, MR; Flesher, DL; Zhang, Y; Rasmussen, E; Henary, HA; Wang, ES

Published Date

  • May 20, 2017

Published In

Volume / Issue

  • 35 / 15_suppl

Start / End Page

  • 7027 - 7027

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2017.35.15_suppl.7027